Monoclonal anti

Inhibition of inflammatory cytokines (Fig. 2) Humanized monoclonal anti-TNF antibodies (Infliximab (Remicade ), Adalimumab (Humira )) bind with high selectivity to human TNF-a and neutralize its activity. Thereby, infliximab decreases the effects of enhanced TNF levels during inflammatory disease such as production of proteases, chemokines, adhesion molecules, cyclooxygenase products (prostaglandins), and proinflammatory molecules such as interleukin-1 and -6. The antibodies may also recognize membrane-bound TNF-a on lymphocytes and other immune cells. These cells may subsequently become apoptotic or are eliminated via Fc-receptor-mediated phagocytosis. 

Zhang XQ, Sorensen M, Fung M, Schooley RT (2006) Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20), Antimicrob Agents Chemother 50 2231-2233... 

The approximate location of the epitopes for more than 40 monoclonal anti-ATPase antibodies has been mapped to various regions within the cytoplasmic domain of the Ca " -ATPase [285,302-304]. All antibodies were found to bind with high affinity to denatured Ca -ATPase, but the binding to the native enzyme showed significant differences depending on the location of antigenic sites within the ATPase molecule. 

Omalizumab is a recombinant humanized monoclonal anti-IgE antibody that inhibits binding of IgE to receptors on mast cells and basophils, resulting in the inhibition of mediator release and attenuation of the early- and late-phase allergic response. It may be a treatment option for moderate to severe persistent asthmatics 12 years of age or older whose asthma is not controlled by inhaled corticosteroids and who have a positive skin test or in vitro reactivity to perennial allergens.37 Omalizumab significantly decreases inhaled corticosteroid use, number and length of exacerbations, and increases asthma-related quality of life.37... 

VI3. Vora, S and Francke, U., Assignment of the human gene for liver-type 6-phosphofructokinase isozyme (PFKL) to chromosome 21 by using somatic cell hybrids and monoclonal anti-L antibody. Proc. Natl. Acad. Sci. U.S.A. 78,3738-3742 (1981). 

Pretreatment with monoclonal anti-TNF antibodies prevents mortality (B23, M32) and organ damage (M16) in experimental sepsis. In clinical studies using anti-TNF antibodies, however, the overall benefit of this treatment showed encouraging but no evident results (L22). Recently, the INTERSEPT study suggests a possible role for anti-TNF antibody as an adjunctive therapy, but with no reduction of mortality (C21). There is no plain cause-effect relation between TNF re-... 

In chimpanzees, administration of Fab fragments of a monoclonal anti-F-VII antibody preceding an endotoxin bolus injection effectively blocked the activation of the coagulation pathway (B25). Administration of monoclonal anti-lL-6 under the same experimental conditions attenuated the activation of coagulation, while the fibrinolytic system remained unaltered. However, administration of monoclonal anti-TNF enhanced the tendency to microvascular thrombosis (P17,18). Monoclonal anti-TF antibodies administered to baboons as a pretreatment attenuated coagulopathy after induction of E. coli sepsis in these animals (T4). Primates pretreated with anti-C5a antibodies before infusion of E. coli developed less hypotension and had better survival rates than untreated animals, who developed ARDS and septic shock with a mortality rate of 75% (S35, Z6). No favorable treatment results have been published yet with one of these treatment modalities given to humans. 

Nishikawa, S., Kusakabe, M., Yoshinaga, K., Ogawa, M Hayashi, S-I., Kunisada, T., Era, T., Sakakura, T., and Nishikawa, S. I. (1991). In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody two distinct waves of c-kit-dependency during melanocyte development. EMBO J. 10 2111-2118. 

The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin. Cancer Immunol. Immunother. 25, 31. 

Tada, H., Higuchi, H., Wanatabe, T.M., and Ohuchi, N. (2007) In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 67, 1138-1144. 

Fig. 1.2 Protein blot analysis of human therapeutic protease inhibitor (HTPI) produced in alfalfa cell cultures using different promoters and subcellular targeting peptides as shown. Equal amounts of total soluble proteins from cell cultures were separated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto a polyvinyldifluoride (PVDF) membrane. Monoclonal anti-HTPI IgGs were used for detection.

Tl. Taddei-Peters, W. C., Butman, B. T., Jones, G. R., Venetta, T. M., Macomber, P. F., and Ransom, J. H., Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clin. Chem. (Winston-Salem, NC) 39, 1382-1389 (1993). 

Figure 11.4 Schematic representation of ELISAs for the detection of IFN-a-IFN-tx and HS A-IFN-a aggregates. IFN-a-fFN-a aggregates are detected using the same monoclonal anti-fFN-a antibody (LI-1) as capture and detection antibodies. HSA-IFN-a aggregates are captured by the anti-IFN-a antibody LI-1, and IFN-a-bound HSA is identified by a polyclonal and anti-HSA antibody. For simplicity, aggregates are illustrated at a 1 1 molar ratio (HRP = horseradish peroxidase).

Foran, J., Norton, A.J., Micallef, L, Taussig, D., Amess, J., Rohatiner, A., and Lister, T.A., Loss of CD20 expression following treatment with Rituximab (chimeric monoclonal anti-CD20) a retrospective cohort analysis, Br.. Haematol., 114, 881-883, 2001. 

Molecular modeling has been applied to investigate peptide mimicry of the Lewis Y tetrasaccharide. The peptide APWLYGPA, first reported by Hoess et al. [12], and shown to be a mimotope [54], binds to the monoclonal anti-Lewis Y antibody B3. A model of the antibody was constructed com-... 

Apply rhodamine-labeled mouse monoclonal anti-F antibody... 

Cordell, J. L., Falini, B., Erber, W. N., Ghosh, A. K., Abdulaziz, Z., MacDonald, S., Pulford, K. A. F., Stein, H., and Mason, D. Y. (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline-phosphatase (APAAP complexes). J. Histochem. Cytochem. 32, 219-229. 

Bansal, G., Martenson, R. E., Leveille, P., and Campagnoni, A. T. (1987) Characterization of a novel monoclonal anti-myelin basic protein antibody use in immunoblotting and immunohistochemical studies. J. Neuroimmunol. 15, 279-294. 

De Martino, T., Minenkova, O., Bombardi, V, Anastasi, A. M., Lindstedt, R., Felici, F., De Santis, R., Verdoliva, A. Identification and refinement of a peptide affinity ligand with unique specificity for a monoclonal anti-tenascin-C antibody by screening of a phage display library. / Chromatogr A 2006, 1107, 182-191. 

Primary antibody Monoclonal anti-GAPDH antibody and monoclonal anti-p-actin antibody from mouse (see Note 1). 

Fig. 6 Evaluation of phosvitin binding to monoclonal anti-phosphoserine antibody by ACE using mobility-shift analysis and UV detection. Peaks M, internal peptide marker mAb, free monoclonal anti-phosphoserine antibody mAb-hpAg complex, monoclonal anti-phosphoserine antibody complexed with homopolyvalent phosvitin antigen. The buffer contained phosvitin within a concentration from 0 to 60 /xM. (Reprinted with permission from Ref. 27. Copyright 1997 Academic Press.)... 

Monoclonal antibody-binding affinity was determined by microchip-based capillary electrophoresis with LIF detection (33). The mixing was carried out off-chip, and the on-chip separations were performed in less than 60 s (Fig. 9). A Scatchard plot analysis resulted in an affinity constant for the monoclonal anti-BSA antibody to fluorescently labeled BSA (BSA ) of... 

---